Acyl-coenzyme A:cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis

Current Opinion in Investigational Drugs

Volumn 4, Issue 9, 2003, Pages 1095-1099

  Miyazaki, Akira ^a   Sakai, Masakazu ^b   Sakamoto, Yuichiro ^b   Horiuchi, Seikoh ^b  

^a SHOWA UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

ACAT; apoE; Cholesterol; Chylomicron; VLDL

Indexed keywords

1 BENZYL 1 [[3 (4 CHLOROPHENYL) 5 METHYL 2 BENZOFURANYL]METHYL] 3 (2,4,6 TRIFLUOROPHENYL)UREA; 2,2 DIMETHYL N (2,4,6 TRIMETHOXYPHENYL)DODECANAMIDE; 3 [N (2,2,5,5 TETRAMETHYL 1,3 DIOXANE 4 CARBONYL)AMINO]PROPIONIC ACID 2 (3 NEOPENTYL 3 NONYLUREIDO)CYCLOHEXYL ESTER; 3 DECYLDIMETHYLSILYL N [2 (4 METHYLPHENYL) 1 PHENYLETHYL]PROPIONAMIDE; ALITRETINOIN; APOLIPOPROTEIN B; ATORVASTATIN; AVASIMIBE; CALCITRIOL; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE 1; CHOLESTEROL ACYLTRANSFERASE 2; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHYLOMICRON; E 5324; EFLUCIMIBE; ENZYME INHIBITOR; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N (2,6 DIISOPROPYLPHENYL)TETRADECYLTHIOACETAMIDE; RETINOIC ACID; SIMVASTATIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANEURYSM RUPTURE; ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL TRANSFORMATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CHOLESTEROL METABOLISM; CHOLESTEROL STONE; CLINICAL TRIAL; COLON CANCER; CORONARY ARTERY DILATATION; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DIET THERAPY; DISEASE CONTROL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME REGULATION; FOAM CELL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INHIBITION KINETICS; INTESTINE; LIVER; MACROPHAGE; MONOCYTE; NONHUMAN; POSTOPERATIVE COMPLICATION; PROTEIN ASSEMBLY; PROTEIN CONTENT; PROTEIN SECRETION; PROTEIN SYNTHESIS; RESTENOSIS; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; ARTERIOSCLEROSIS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMANS; HYPERCHOLESTEROLEMIA; INTESTINES; LIVER; MACROPHAGES; STEROL O-ACYLTRANSFERASE;

EID: 0142183214     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Chang TY, Chang CC, Cheng D: Acyl-coenzyme A:cholesterol acyltransferase. Annu Rev Biochem (1997) 66:613-638.
2. Rudel LL, Lee RG, Cockman TL: Acyl-coenzyme A:cholesterol acyltransferase type 1 and 2: Structure and function in atherosclerosis. Curr Opin Lipidol (2001) 12(2):121-127.
3. Chang TY, Chang CCY, Lin S, Yu C, Li BL, Miyazaki A: Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2. Curr Opin Lipidol (2001) 12(3):289-296.
4. Buhman KF, Accad M, Farese RV Jr: Mammalian acyl-CoA:cholesterol acyltransferases. Biochim Biophys Acta (2000) 1529(1-3):142-154.
5. Roth BD: ACAT inhibitors: Evolution from cholesterol-absorption inhibitors to antiatherosclerotic agents. Drug Disc Today (1998) 3(1):19-25. An excellent review that describes the history of ACAT inhibitors.
6. Matsuo M, Hashimoto M, Suzuki J, Iwanami K, Tomoi M, Shimomura K: Difference between normal and WHHL rabbits in susceptibility to the adrenal toxicity of an acyl-CoA:cholesterol acyltransferase inhibitor, FR145237. Toxicol Appl Pharmacol (1996) 140(2):387-392.
7. Insull W Jr, Koren M, Davignon J, Sprecher D, Schrott H, Keilson LM, Brown AS, Dujovne CA, Davidson MH, McLain R, Heinonen T: Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis (2001) 157(1):137-144. Treatment with avasimibe did not significantly reduce plasma cholesterol levels but reduced triglyceride levels in this clinical trial.
8. Chang CC, Huh HY, Cadigan KM, Chang TY: Molecular cloning and functional expression of human acyl-coenzyme A:cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells. J Biol Chem (1993) 268(28):20747-20755.
9. Oelkers P, Behari A, Cromley D, Billheimer JT, Sturley SL: Characterization of two human genes encoding acyl coenzyme A:cholesterol acyltransferase-related enzymes. J Biol Chem (1998) 273(41):26765-26771.
10. Miyazaki A, Sakashita N, Lee O, Takahashi K, Horiuchi S, Hakamata H, Morganelli PM, Chang CC, Chang TY: Expression of ACAT-1 protein in human atherosclerotic lesions and cultured human monocytes-macrophages. Arterioscler Thromb Vasc Biol (1998) 18(10):1568-1574.
11. Sakashita N, Miyazaki A, Takeya M, Horiuchi S, Chang CC, Chang TY, Takahashi K: Localization of human acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT1) in macrophages and in various tissues. Am J Pathol (2000) 156(1):227-236. Immunohistochemical studies of human tissues demonstrated marked expression of ACAT1 in macrophages, adrenal glands and sebaceous glands.
12. Chang CC, Sakashita N, Ornvold K, Lee O, Chang ET, Dong R, Lin S, Lee CY, Strom SC, Kashyap R, Fung JJ et al.: Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. J Biol Chem (2000) 275(36):28083-28092. This paper showed that ACAT2 is expressed in fetal human liver but not in adult human liver. ACAT2 is expressed exclusively in intestine in adult human.
13. Wang H, Germain SJ, Benfield PP, Gillies PJ: Gene expression of acyl-coenzyme-A:cholesterol-acyltransferase is upregulated in human monocytes during differentiation and foam cell formation. Arterioscler Thromb Vasc Biol (1996) 16(6):809-814.
14. 3 or 9-cis-retinoic acid in undifferentiated THP-1 cells. J Lipid Res (2001) 42(2):181-187.
15. Panousis CG, Zuckerman SH: Regulation of cholesterol distribution in macrophage-derived foam cells by interferon-γ. J Lipid Res (2000) 41(1):75-83.
16. Yang JB, Duan ZJ, Yao W, Lee O, Yang L, Yang XY, Sun X, Chang CC, Chang TY, Li BL: Synergistic transactivation of human acyl-coenzyme A:cholesterol acyltransferase-1 gene by interferon-γ and all-trans-retinoic acid in THP-1 cells. J Biol Chem (2001) 276(24):20989-20998.
17. Seo T, Oelkers PM, Giattina MR, Worgall TS, Sturley SL, Deckelbaum RJ: Differential modulation of ACAT1 and ACAT2 transcription and activity by long chain free fatty acids in cultured cells. Biochemistry (2001) 40(15):4756-4762.
18. Tanaka H, Otsuka I, Kogushi M, Kimura T, Fujimori T, Saeki T, Hayashi K, Kobayashi H, Yamada T, Hiyoshi H et al.: Effects of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbits. Atherosclerosis (1994) 107(2):187-201.
19. Asami Y, Yamagishi I, Murakami S, Araki H, Tsuchida K, Higuchi S: HL-004, the ACAT inhibitor, prevents the progression of atherosclerosis in cholesterol-fed rabbits. Life Sci (1998) 62(12):1055-1063.
20. Matsuo M, Ito F, Konto A, Aketa M, Tomoi M, Shimomura K: Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits. Evidence for a direct effect on the arterial wall. Biochim Biophys Acta (1995) 1259(3):254-260.
21. Bocan TMA, Krause BR, Rosebury WS, Mueller SB, Lu X, Dagle C, Major T, Lathia C, Lee H: The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol (2000) 20(1):70-79. Treatment of cholesterol-fed rabbits with avasimibe reduced the number of macrophages as well as expression of matrix metalloprotease-2 in the atherosclerotic lesions without affecting plasma cholesterol levels, suggesting that ACAT inhibitors contribute to plaque stabilization.
22. Aragane K, Kojima K, Fujinami K, Kamei J, Kusunoki J: Effect of F-1394, an acyl-CoA:cholesterol acyltransferase inhibitor, on atherosclerosis induced by high cholesterol diet in rabbits. Atherosclerosis (2001) 158(1):139-145.
23. Aragane K, Fujinami K, Kojima K, Kusunoki J: ACAT inhibitor F-1394 prevents intimal hyperplasia induced by balloon injury in rabbits. J Lipid Res (2001) 42(4):480-488. F-1394 was shown to suppress intimal thickening in a rabbit model of balloon injury, suggesting potential efficacy of ACAT inhibitors for treatment of restenosis after angioplasty.
24. Kusunoki J, Hansoty DK, Aragane K, Fallon JT, Badimon JJ, Fisher EA: Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation (2001) 103(21):2604-2609. Although disruption of macrophage ACAT-1 enhanced atherosclerotic lesions in LDL receptor-null mice, this paper clearly showed suppression of atherosclerosis in apoE knockout mice by an ACAT inhibitor, F-1394.
25. Delsing DJM, Offerman EH, Van Duyvenvoorde W, Van Der Boom H, De Wit EC, Gijbels MJ, Van Der Laarse A, Jukema JW, Havekes LM, Princen HM: Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation (2001) 103(13):1778-1786.
26. Kang S, Davis RA: Cholesterol and hepatic lipoprotein assembly and secretion. Biochim Biophys Acta (2000) 1529(1-3):223-230.
27. Hussain MM: A proposed model for the assembly of chylomicrons. Atherosclerosis (2000) 148(1):1-15.
28. Gordon DA, Jamil H: Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly. Biochim Biophys Acta (2000) 1486(1):72-83.
29. Wilcox LJ, Barrett PHR, Newton RS, Huff MW: ApoB100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011: An effect associated with enhanced intracellular degradation of ApoB. Arterioscler Thromb Vasc Biol (1999) 19(4):939-949.
30. Taghibiglou C, Van Iderstine SC, Kulinski A, Rudy D, Adeli K: Intracellular mechanisms mediating the inhibition of ApoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. Biochem Pharmacol (2002) 63(3):349-360.
31. Huff MW, Telford DE, Barrett PH, Billheimer JT, Gillies PJ: Inhibition of hepatic ACAT decreases apoB secretion in miniature pigs fed a cholesterol-free diet. Arterioscler Thromb (1994) 14(9):1498-1508.
32. Carr TP, Hamilton RL Jr, Rudel LL: ACAT inhibitors decrease secretion of cholesteryl esters and apolipoprotein B by perfused livers of African green monkeys. J Lipid Res (1995) 36(1):25-36.
33. Post SM, Zoeteweij JP, Bos MHA, De Wit ECM, Havinga R, Kuipers F, Princen HMG: Acyl-coenzyme A:cholesterol acyltransferase inhibitor, avasimibe, stimulated bile acid synthesis and cholesterol 7α-hydroxylase in cultured rat hepatocytes and in vivo in the rat. Hepatology (1999) 30(2):491-500. This paper demonstrated upregulation of cholesterol 7α-hydroxylase, a key enzyme for bile acid synthesis, by an ACAT inhibitor, proposing a novel mechanism of cholesterol lowering by ACAT inhibitors.
34. 48 secretion in Caco2 cells. Atherosclerosis (2002) 161(1):55-63.
35. Jiao S, Matsuzawa Y, Matsubara K, Kihara S, Nakamura T, Tokunaga K, Kubo M, Tarui S: Increased activity of intestinal acyl-CoA:cholesterol acyltransferase in rats with streptozotocin-induced diabetes and restoration by insulin supplementation. Diabetes (1988) 37(3):342-346.
36. Kusunoki J, Aragane K, Kitamine T, Kozono H, Kano K, Fujinami K, Kojima K, Chiwata T, Sekine Y: Postprandial hyperlipidemia in streptozotocin-induced diabetic rats is due to abnormal increase in intestinal acyl-coenzyme A:cholesterol acyltransferase activity. Arterioscler Thromb Vasc Biol (2000) 20(1):171-178.
37. Sakuma Y, Hagihara H, Nagayoshi A, Ohne K, Mutoh S, Ito Y, Nakahara K, Notsu Y, Okuhara M: Effects of FR145237, an acyl-CoA:cholesterol acyltransferase inhibitor, on diet-induced hypercholesterolemia in diabetic rats. Life Sci (1997) 60(6):351-356
38. Bernard DW, Rodriguez A, Rothblat GH, Glick JM: Influence of high density lipoprotein on esterified cholesterol stores in macrophages and hepatoma cells. Arteriosclerosis (1990) 10(1):135-144.
39. Hakamata H, Miyazaki A, Sakai M, Suginohara Y, Sakamoto Y, Horiuchi S: Species difference in cholesteryl ester cycle and HDL-induced cholesterol efflux from macrophage foam cells. Arterioscler Thromb (1994) 14(11):1860-1865.
40. Rodriguez A, Bachorik PS, Wee SB: Novel effects of the acylcoenzyme A:cholesterol acyltransferase inhibitor 58-035 on foam cell development in primary human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol (1999) 19(9):2199-2206.
41. Meiner VL, Cases S, Myers HM, Sande ER, Bellosta S, Schambelan M, Pitas RE, McGuire J, Herz J, Farese RV Jr: Disruption of the acyl-CoA:cholesterol acyltransferase gene in mice: Evidence suggesting multiple cholesterol esterification enzymes in mammals. Proc Natl Acad Sci USA (1996) 93(24):14041-14046.
42. Cases S, Novak S, Zheng YW, Myers HM, Lear SR, Sande E, Welch CB, Lusis AJ, Spencer TA, Krause BR, Erickson SK et al: ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase. Its cloning, expression, and characterization. J Biol Chem (1998) 273(41):26755-26764.
43. Accad M, Smith SJ, Newland DL, Sanan DA, King LE Jr, Linton MF, Fazio S, Farese RV Jr: Massive xanthomatosis and altered composition of atherosclerosis in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1. J Clin Invest (2000) 105(6):711-719.
44. Yagyu H, Kitamine T, Osuga J, Tozawa R, Chen Z, Kaji Y, Oka T, Perrey S, Tamura Y, Ohashi K, Okazaki H et al: Absence of ACAT-1 attenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia. J Biol Chem (2000) 275(28):21324-21330.
45. Fazio S, Major AS, Swift LL, Gleaves LA, Accad M, Linton MF, Farese RV Jr: Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest (2001) 107(2):163-171. Disruption of macrophage ACAT1 in LDL receptor-deficient mice unexpectedly worsened the atherosclerotic lesions, suggesting a side effect of ACAT inhibitors at high dosages.
46. Buhman KK, Accad M, Novak S, Choi RS, Wong JS, Hamilton RL, Turley S, Farese RV Jr: Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. Nat Med (2000) 6(12):1341-1347. ACAT2 null mice showed resistance to diet-induced hypercholesterolemia and gallstone formation, suggesting that ACAT inhibitors are useful for preventing formation of cholesterol gallstones.
47. Huff MW, Burnett JR: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr Opin Lipidol (1997) 8(3):138-145.
48. Burnett JR, Wilcox LJ, Huff MW: Acyl coenzyme A:cholesterol acyltransferase inhibition and hepatic apolipoprotein B secretion. Clin Chim Acta (1999) 286(1-2):231-242.
49. Bocan TMA, Krause BR, Rosebury WS, Lu X, Dagle C, Mueller SB, Auerback B: The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression. Atherosclerosis (2001) 157(1):97-105.
50. Bocan TMA, Mueller SB, Brown EQ, Lee P, Bocan MJ, Rea T, Pape ME: HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbits. Atherosclerosis (1998) 139(1):21-30.
51. Burnett JR, Huff MW: Avasimibe (Pfizer). Curr Opin Investig Drugs (2002) 3(9):1328-1333.
52. Tardif JC, Gregoire J, Lesperance J, Lamber J, L'Allier PL, Rodes J, Anderson T, Blue JW, Imus J, Heinonen T: Design features of the avasimibe and progression of coronary lesions assessed by intravascular ultrasound (A-PLUS) clinical trials. Am Heart J (2002) 144(4):589-596.
53. Bocan TMA, Mueller SB, Brown EQ, Lee P, Bocan MJ, Rea T, Pape ME: HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbits. Atherosclerosis (1998) 139(1):21-30.